Chimeric antigen receptor gamma delta T cell therapy (Hebei Senlang Biotechnology)

N/A

Report date: 2025/05/29 11:47:53

Base Information

Drug NameChimeric antigen receptor gamma delta T cell therapy (Hebei Senlang Biotechnology)
Drug Alias NameCAR-γδT cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Senlang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A